Advanced search
1 file | 326.08 KB

Treatment of allergic rhinitis using mobile technology with real world data : the MASK observational pilot study

(2018) ALLERGY. 73(9). p.1763-1774
Author
Organization
Abstract
Background: Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect real-world everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology. Methods: A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. Results: A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control). Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses.
Keywords
mHealth, mobile technology, observational study, rhinitis, treatment, GUIDED SELF-MANAGEMENT, QUALITY-OF-LIFE, TRADITIONAL TREATMENT, CONTROLLED-TRIAL, DOUBLE-BLIND, ASTHMA, AZELASTINE, IMPACT, CARE, FLUTICASONE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 326.08 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bousquet, J, S Arnavielhe, A Bedbrook, G Alexis-Alexandre, M van Eerd, R Murray, GW Canonica, et al. 2018. “Treatment of Allergic Rhinitis Using Mobile Technology with Real World Data : the MASK Observational Pilot Study.” Allergy 73 (9): 1763–1774.
APA
Bousquet, J, Arnavielhe, S., Bedbrook, A., Alexis-Alexandre, G., van Eerd, M., Murray, R., Canonica, G., et al. (2018). Treatment of allergic rhinitis using mobile technology with real world data : the MASK observational pilot study. ALLERGY, 73(9), 1763–1774.
Vancouver
1.
Bousquet J, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M, Murray R, et al. Treatment of allergic rhinitis using mobile technology with real world data : the MASK observational pilot study. ALLERGY. 2018;73(9):1763–74.
MLA
Bousquet, J, S Arnavielhe, A Bedbrook, et al. “Treatment of Allergic Rhinitis Using Mobile Technology with Real World Data : the MASK Observational Pilot Study.” ALLERGY 73.9 (2018): 1763–1774. Print.
@article{8549714,
  abstract     = {Background: Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect real-world everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology. 
Methods: A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. 
Results: A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control). 
Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses.},
  author       = {Bousquet, J and Arnavielhe, S and Bedbrook, A and Alexis-Alexandre, G and van Eerd, M and Murray, R and Canonica, GW and Illario, M and Menditto, E and Passalacqua, G and Stellato, C and Triggiani, M and Carreiro-Martins, P and Fonseca, J and Morais Almeida, M and Nogueira-Silva, L and Pereira, AM and Todo Bom, A and Bosse, I and Caimmi, D and Demoly, P and Devillier, P and Fontaine, JF and Just, J and Onorato, GL and Kowalski, ML and Kuna, P and Samolinski, B and Anto, JM and Mullol, J and Valero, A and Tomazic, PV and Bergmann, KC and Keil, T and Klimek, L and M{\"o}sgues, R and Shamai, S and Zuberbier, T and Murphy, E and McDowall, P and Price, D and Ryan, D and Sheikh, A and Chavannes, NH and Fokkens, WJ and Kvedariene, V and Valiulis, A and Bachert, Claus and Hellings, PW and Kull, I and Mel{\'e}n, E and Wickman, M and Bindslev-Jensen, C and Eller, E and Haahtela, T and Valovirta, E and Papadopoulos, NG and Annesi-Maesano, I and Bewick, M and Bosnic-Anticevich, S and Cruz, AA and De Vries, G and Gemicioglu, B and Larenas-Linnemann, D and Laune, D and Mathieu-Dupas, E and O'Hehir, RE and Portejoie, F and Siroux, V and Spranger, O and VandenPlas, O and Yorgancioglu, A},
  issn         = {0105-4538},
  journal      = {ALLERGY},
  keyword      = {mHealth,mobile technology,observational study,rhinitis,treatment,GUIDED SELF-MANAGEMENT,QUALITY-OF-LIFE,TRADITIONAL TREATMENT,CONTROLLED-TRIAL,DOUBLE-BLIND,ASTHMA,AZELASTINE,IMPACT,CARE,FLUTICASONE},
  language     = {eng},
  number       = {9},
  pages        = {1763--1774},
  title        = {Treatment of allergic rhinitis using mobile technology with real world data : the MASK observational pilot study},
  url          = {http://dx.doi.org/10.1111/all.13406},
  volume       = {73},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: